Turkish Thoracic Journal
Original Article

Evaluation of serum resistin, visfatin and chemerin levels in patients with lung cancer and chronic obstructive pulmonary disease

1.

Department of Pulmonary Medicine, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

Turk Thorac J 0; 5: 0-0
DOI: 10.5152/TurkThoracJ.2019.19001
Read: 324 Downloads: 38 Published: 18 July 2019

Abstract

Objective: Cachexia is an important problem in lung cancer and COPD. Some studies report an association between adipokines and cachexia. Our study aimed to investigate the association of three recently described new adipokines, namely resistin, visfatin, and chemerin with lung cancer and COPD.

 

Methods: Thirty patients with non-small-cell lung cancer (NSCLC), 30 patients with COPD and 30 healthy volunteers were included in the study. A statistically significant weight loss was found in COPD and lung cancer patients compared to the control group (p<0.001). Among the bio-markers, only resistin levels were significantly higher in cachectic patients compared to the patients without weight loss in all groups (p=0.006). Resistin level was significantly higher in patients with COPD (p=0.002). Visfatin level, however, was significantly higher in the control group (p=0.001). We found that a higher biomass exposure resulted in a significant increase in the resistin level (p=0.007) and a significant decrease in the visfatin level (p=0.001) in the patient groups. In addition, high asbestos exposure levels were associated with lower visfatin levels (p=0.001). For all groups, no statistically significant relationship was found between chemerin levels and weight loss or other variables. Furthermore, the type and stage of lung cancer were not associated with the bio-markers.

 

Results: No significant relationship was found between the bio-markers and lung cancer type (adenocarcinoma or squamous cell lung cancer), tumor stage, lymph node stage, and metastasis stage. There was no relationship between the bio-markers by TNM and GOLD stages (p>0.05). We observed no findings strong enough to support the use of these molecules as markers of disease stage or cachexia.

 

Conclusion: In conclusion, resistin, visfatin and chemerin cannot be used as potential biomarkers in patients with lung cancer or COPD nor as markers of disease stage or cachexia.

 

Cite this article as: Göktepe M, Korkmaz C, Zamani A, et al. Evaluation of serum resistin, visfatin and chemerin levels in patients with lung cancer and chronic obstructive pulmonary disease. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.18202

EISSN 2149-2530
3